Tag: M.W:400-500

Most of the compounds have physiologically active properties, and their biological properties are often attributed to the heteroatoms contained in their molecules, and most of these heteroatoms also appear in cyclic structures. A Journal, Dopovidi Akademii Nauk Ukrains’koi RSR, Seriya B: Geologiya, Geofizika, Khimiya ta Biologiya called Reactivity of neutral platinum(II) complexes, Author is Panasyuk, V. D.; Malashok, N. F., which mentions a compound: 15227-42-6, SMILESS is [Cl-][Pt+2]([N]1=CC=CC=C1)([Cl-])[N]2=CC=CC=C2, Molecular C10H10Cl2N2Pt, HPLC of Formula: 15227-42-6.

Kinetic data were obtained for the hydrolysis of [PtenCl2], cis- and trans-[Pt(NH3)2Cl2], cis-[Ptpy2Cl2], and [Pten(NO2)Cl] and for the replacement of Cl by NH3 in trans-[Pt(NH3)2Cl2]. The medium was H2O and mixtures of H2O with MeOH, EtOH, or Me2CO, the concentration of the organic component being 30 and 40 weight % in the hydrolysis and replacement reactions, resp. The lowering of the reaction rate in the presence of the organic component is explained by a structure-dependent contribution of the component to the solvation energy of an intermediate complex. The hydrolysis reaction is assumed to proceed in 2 steps: (1) formation of an intermediate complex by a slow coordination of the H2O mol. to the Pt2+ central ion without release of Cl- and (2) by a quick release of Cl-. The bond polarization occurs during the 1st step and the rate constant, k, should equal the ratio of the activity coefficients of the initial and activated complexes.

Although many compounds look similar to this compound(15227-42-6)HPLC of Formula: 15227-42-6, numerous studies have shown that this compound(SMILES:[Cl-][Pt+2]([N]1=CC=CC=C1)([Cl-])[N]2=CC=CC=C2), has unique advantages. If you want to know more about similar compounds, you can read my other articles.

Reference:
Tetrahydroisoquinoline – Wikipedia,
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

The preparation of ester heterocycles mostly uses heteroatoms as nucleophilic sites, which are achieved by intramolecular substitution or addition reactions. Compound: cis-Dichlorobis(pyridine)platinum(II)( cas:15227-42-6 ) is researched.Category: tetrahydroisoquinoline.Teicher, Beverly A.; Rockwell, Sara; Lee, Jonathan B. published the article 《Radiosensitization of EMT6 cells by four platinum complexes》 about this compound( cas:15227-42-6 ) in International Journal of Radiation Oncology, Biology, Physics. Keywords: radiosensitization EMT cell platinum complex; oxygen radiosensitization platinum complex. Let’s learn more about this compound (cas:15227-42-6).

The radiosensitization of oxygenated and hypoxic exponentially growing EMT6 cells in vitro was measured. The dose modifying factors obtained with 200 and 400 μM trans-bis(2-nitroimidazole)dichloroplatinum II (NIPt) in hypoxic cells were 1.5 and 2.1, resp. For trans-bis(2-amino-5-nitrothiazole)dichloroplatinum II (Plant) under the same conditions, the dose modifying factor was 1.5 at 200 μM and 1.8 at 400 μM. Neither compound sensitized oxygenated cells when tested under similar protocols. Unlike the trans complexes, (1,2-diamino-4-nitrobenzene)dichloroplatinum II (Plato) was cytotoxic toward the hypoxic cells in the absence of x-rays. The time course of cytotoxicity for 100 μM Plato in exponentially growing cells showed rapid killing of hypoxic cells, and much less toxicity toward oxygenated cells. In radiosensitization studies, dose modifying factors of 1.6 and 2.0 were found with 200 and 400 μM Plato, resp., in hypoxic cells. The compound did not sensitize aerobic cells. The well known Pt complex cis-dipyridinedichloroplatinum II (PyPt) represents a cis-Pt heterocyclic aromatic complex that does not have a nitro-functionality. The dose modifying factor obtained with 400 μM PyPt in hypoxic cells was 1.7. On a molar basis, the nitro-functional Pt complexes appear to be more effective as hypoxic cell radiosensitizers than the corresponding free ligands.

Although many compounds look similar to this compound(15227-42-6)Category: tetrahydroisoquinoline, numerous studies have shown that this compound(SMILES:[Cl-][Pt+2]([N]1=CC=CC=C1)([Cl-])[N]2=CC=CC=C2), has unique advantages. If you want to know more about similar compounds, you can read my other articles.

Reference:
Tetrahydroisoquinoline – Wikipedia,
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

Most of the compounds have physiologically active properties, and their biological properties are often attributed to the heteroatoms contained in their molecules, and most of these heteroatoms also appear in cyclic structures. A Journal, Article, European Journal of Medicinal Chemistry called Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma, Author is Jiang, Baishan; Jiang, Jie; Kaltheuner, Ines H.; Iniguez, Amanda Balboni; Anand, Kanchan; Ferguson, Fleur M.; Ficarro, Scott B.; Seong, Bo Kyung Alex; Greifenberg, Ann Katrin; Dust, Sofia; Kwiatkowski, Nicholas P.; Marto, Jarrod A.; Stegmaier, Kimberly; Zhang, Tinghu; Geyer, Matthias; Gray, Nathanael S., which mentions a compound: 882562-40-5, SMILESS is ClC1=NC(C2=CN(C3=C2C=CC=C3)S(=O)(=O)C2=CC=CC=C2)=C(Cl)C=N1, Molecular C18H11Cl2N3O2S, Related Products of 882562-40-5.

Development of inhibitors targeting CDK12/13 is of increasing interest as a potential therapy for cancers as these compounds inhibit transcription of DNA damage response (DDR) genes. We previously described THZ531, a covalent inhibitor with selectivity for CDK12/13. In order to elucidate structure-activity relationship (SAR), we have undertaken a medicinal chem. campaign and established a focused library of THZ531 analogs. Among these analogs, BSJ-01-175 demonstrates exquisite selectivity, potent inhibition of RNA polymerase II phosphorylation, and downregulation of CDK12-targeted genes in cancer cells. A 3.0 Å co-crystal structure with CDK12/CycK provides a structural rational for selective targeting of Cys1039 located in a C-terminal extension from the kinase domain. With moderate pharmacokinetic properties, BSJ-01-175 exhibits efficacy against an Ewing sarcoma tumor growth in a patient-derived xenograft (PDX) mouse model following 10 mg/kg once a day, i.p. administration. Taken together, BSJ-01-175 represents the first selective CDK12/13 covalent inhibitor with in vivo efficacy reported to date.

Although many compounds look similar to this compound(882562-40-5)Related Products of 882562-40-5, numerous studies have shown that this compound(SMILES:ClC1=NC(C2=CN(C3=C2C=CC=C3)S(=O)(=O)C2=CC=CC=C2)=C(Cl)C=N1), has unique advantages. If you want to know more about similar compounds, you can read my other articles.

Reference:
Tetrahydroisoquinoline – Wikipedia,
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

Electric Literature of C10H10Cl2N2Pt. The mechanism of aromatic electrophilic substitution of aromatic heterocycles is consistent with that of benzene. Compound: cis-Dichlorobis(pyridine)platinum(II), is researched, Molecular C10H10Cl2N2Pt, CAS is 15227-42-6, about Cis-bis(pyridine)dichloro derivatives of platinum(IV). Author is Chernyaev, I. I.; Zheligovskaya, N. N.; Bavina, T. V..

The complexes Pt(py)2Cl2XNO2 (X = Cl-, Br-) and Pt(py)2Cl2(OH)NO2 were precipitated by adding 5-10 ml. H2O to mixtures of equivalent amounts of Pt(py)2Cl2(NO2)NO3 (I) and KCl, KBr, or KOH, resp. I reacts with KI to give a mixture of Pt(py)2Cl2I2 and Pt(py)2Cl2INO2. Chlorination of Pt(py)2Cl2 yields [Pt(py)2Cl2]Cl2. [Pt(py)2Cl2][Pt(py)2Cl2(OH)2] was obtained from Pt(py)2Cl2 and 10% aqueous H2O2 at room temperature after standing for 24 hrs. Individual species were identified by x-ray diffraction tests. The aqueous solutions of Pt(py)2Cl2XNO2 undergo hydrolysis according to: Pt(py)2Cl2XNO2 + H2O ⇌ [Pt(py)2Cl2X(H2O)]+ + NO2-, whereas the aqueous solutions of Pt(py)2Cl2(OH)2 and [Pt(py)2Cl2]Cl2 are considerably more stable. Solutions of Pt(py)2Cl2Br2 partially decompose in light to Pt(py)2Cl2, HBrO, and HBr, resp.

Although many compounds look similar to this compound(15227-42-6)Electric Literature of C10H10Cl2N2Pt, numerous studies have shown that this compound(SMILES:[Cl-][Pt+2]([N]1=CC=CC=C1)([Cl-])[N]2=CC=CC=C2), has unique advantages. If you want to know more about similar compounds, you can read my other articles.

Reference:
Tetrahydroisoquinoline – Wikipedia,
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

Recommanded Product: cis-Dichlorobis(pyridine)platinum(II). So far, in addition to halogen atoms, other non-metallic atoms can become part of the aromatic heterocycle, and the target ring system is still aromatic. Compound: cis-Dichlorobis(pyridine)platinum(II), is researched, Molecular C10H10Cl2N2Pt, CAS is 15227-42-6, about Spectroscopic study of square planar compounds of platinum(II) and palladium(II) with substituted pyridines. I. Vibrations of the ligands.

The ir spectra of methylpyridine Pt(II) and Pd(II) complexes were observed at 400-1700 cm-1. Bands were obtained which were displaced by coordination of the ligand or which were characteristics of cis and trans configurations of the planar complexes.

Compounds in my other articles are similar to this one(cis-Dichlorobis(pyridine)platinum(II))Recommanded Product: cis-Dichlorobis(pyridine)platinum(II), you can compare them to see their pros and cons in some ways,such as convenient, effective and so on.

Reference:
Tetrahydroisoquinoline – Wikipedia,
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

Category: tetrahydroisoquinoline. So far, in addition to halogen atoms, other non-metallic atoms can become part of the aromatic heterocycle, and the target ring system is still aromatic. Compound: 3-(2,5-Dichloropyrimidin-4-yl)-1-(phenylsulfonyl)-1H-indole, is researched, Molecular C18H11Cl2N3O2S, CAS is 882562-40-5, about Discovery of SY-5609: A Selective, Noncovalent Inhibitor of CDK7.

CDK7 has emerged as an exciting target in oncol. due to its roles in two important processes that are misregulated in cancer cells: cell cycle and transcription. This report describes the discovery of SY-5609, a highly potent (sub-nM CDK7 Kd) and selective, orally available inhibitor of CDK7 that entered the clinic in 2020 (ClinicalTrials.gov Identifier: NCT04247126). Structure-based design was leveraged to obtain high selectivity (>4000-times the closest off target) and slow off-rate binding kinetics desirable for potent cellular activity. Finally, incorporation of a phosphine oxide as an atypical hydrogen bond acceptor helped provide the required potency and metabolic stability. The development candidate SY-5609 displays potent inhibition of CDK7 in cells and demonstrates strong efficacy in mouse xenograft models when dosed as low as 2 mg/kg.

Compounds in my other articles are similar to this one(3-(2,5-Dichloropyrimidin-4-yl)-1-(phenylsulfonyl)-1H-indole)Category: tetrahydroisoquinoline, you can compare them to see their pros and cons in some ways,such as convenient, effective and so on.

Reference:
Tetrahydroisoquinoline – Wikipedia,
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

In general, if the atoms that make up the ring contain heteroatoms, such rings become heterocycles, and organic compounds containing heterocycles are called heterocyclic compounds. An article called Thermal migration of amines in platinum(II) complexes, published in 1978-08-31, which mentions a compound: 15227-42-6, Name is cis-Dichlorobis(pyridine)platinum(II), Molecular C10H10Cl2N2Pt, Product Details of 15227-42-6.

Derivatog. data indicate that the 1st stage of the thermal conversion of (LH)2[PtCl4] (L = NH3, MeNH2, piperidine, pyridine, γ-picoline, PhNH2, p-toluidine, 8-hydroxyquinoline, quinoline) or (enH2)[PtCl4] is the cleavage of HCl and the formation of PtL2Cl2. All the complexes studied fall into 2 groups according to the temperature of the beginning of the process: (1) complexes with a temperature for the start of thermal reaction at 180 – 200° contain amines the basicity constants of which are >10-5 and (2) complexes with decomposition temperatures at 130-50° contain amines the basicity constants of which are <10-8. Compounds in my other articles are similar to this one(cis-Dichlorobis(pyridine)platinum(II))Product Details of 15227-42-6, you can compare them to see their pros and cons in some ways,such as convenient, effective and so on.

Reference:
Tetrahydroisoquinoline – Wikipedia,
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

The chemical properties of alicyclic heterocycles are similar to those of the corresponding chain compounds. Compound: cis-Dichlorobis(pyridine)platinum(II), is researched, Molecular C10H10Cl2N2Pt, CAS is 15227-42-6, about Supramolecular Nanoencapsulation as a Tool: Solubilization of the Anticancer Drug trans-Dichloro(dipyridine)platinum(II) by Complexation with β-Cyclodextrin, the main research direction is beta cyclodextrin trans dichlorodipyridine platinum complex nanoencapsulation solubilization anticancer.Product Details of 15227-42-6.

A novel, water-soluble trans-platinum complex was synthesized by inclusion complexation with β-cyclodextrin. The complexation was confirmed by 1H NMR, FT-IR, TGA, and XRD as well as by SEM and EDX. As the precursor complex is not water-soluble, it is difficult to employ it for biol. applications. Here, we report that the encapsulation with cyclodextrin allowed to solubilize the complex to a solubility value of 1.6 mg/mL. Moreover, the cytotoxicity in vitro of the novel inclusion complex indicated a much higher activity after encapsulation.

Although many compounds look similar to this compound(15227-42-6)Product Details of 15227-42-6, numerous studies have shown that this compound(SMILES:[Cl-][Pt+2]([N]1=CC=CC=C1)([Cl-])[N]2=CC=CC=C2), has unique advantages. If you want to know more about similar compounds, you can read my other articles.

Reference:
Tetrahydroisoquinoline – Wikipedia,
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

Most of the natural products isolated at present are heterocyclic compounds, so heterocyclic compounds occupy an important position in the research of organic chemistry. A compound: 15227-42-6, is researched, SMILESS is [Cl-][Pt+2]([N]1=CC=CC=C1)([Cl-])[N]2=CC=CC=C2, Molecular C10H10Cl2N2PtJournal, Spectroscopy Letters called Spectral studies of some pyridine and bipyridine complexes of platinum(II), Author is Agarwala, Badri Vishal, the main research direction is platinum pyridine bipyridine spectra; UV platinum pyridine bipyridine; magnetic CD platinum pyridine bipyridine.Application In Synthesis of cis-Dichlorobis(pyridine)platinum(II).

Electronic absorption spectra and magnetic CD (MCD) spectra were studied for the square planar complexes cis- and trans-Pt(py)2Cl2 and Pt(2,2′-bipyridine)Cl2(I). Detailed studies were carried out for I due to its fair solubility in many solvents and the solvent effect on its electronic spectra was investigated. The band assignments of the electronic spectra are discussed and are supported by the MCD spectra. NMR and magnetic studies were also carried out on the complexes to further elucidate their configuration. All the complexes studied are diamagnetic in conformity with their square planar arrangement.

Although many compounds look similar to this compound(15227-42-6)Application In Synthesis of cis-Dichlorobis(pyridine)platinum(II), numerous studies have shown that this compound(SMILES:[Cl-][Pt+2]([N]1=CC=CC=C1)([Cl-])[N]2=CC=CC=C2), has unique advantages. If you want to know more about similar compounds, you can read my other articles.

Reference:
Tetrahydroisoquinoline – Wikipedia,
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

The chemical properties of alicyclic heterocycles are similar to those of the corresponding chain compounds. Compound: cis-Dichlorobis(pyridine)platinum(II), is researched, Molecular C10H10Cl2N2Pt, CAS is 15227-42-6, about Radiosensitization of EMT6 cells by four platinum complexes, the main research direction is radiosensitization EMT cell platinum complex; oxygen radiosensitization platinum complex.Category: tetrahydroisoquinoline.

The radiosensitization of oxygenated and hypoxic exponentially growing EMT6 cells in vitro was measured. The dose modifying factors obtained with 200 and 400 μM trans-bis(2-nitroimidazole)dichloroplatinum II (NIPt) in hypoxic cells were 1.5 and 2.1, resp. For trans-bis(2-amino-5-nitrothiazole)dichloroplatinum II (Plant) under the same conditions, the dose modifying factor was 1.5 at 200 μM and 1.8 at 400 μM. Neither compound sensitized oxygenated cells when tested under similar protocols. Unlike the trans complexes, (1,2-diamino-4-nitrobenzene)dichloroplatinum II (Plato) was cytotoxic toward the hypoxic cells in the absence of x-rays. The time course of cytotoxicity for 100 μM Plato in exponentially growing cells showed rapid killing of hypoxic cells, and much less toxicity toward oxygenated cells. In radiosensitization studies, dose modifying factors of 1.6 and 2.0 were found with 200 and 400 μM Plato, resp., in hypoxic cells. The compound did not sensitize aerobic cells. The well known Pt complex cis-dipyridinedichloroplatinum II (PyPt) represents a cis-Pt heterocyclic aromatic complex that does not have a nitro-functionality. The dose modifying factor obtained with 400 μM PyPt in hypoxic cells was 1.7. On a molar basis, the nitro-functional Pt complexes appear to be more effective as hypoxic cell radiosensitizers than the corresponding free ligands.

Although many compounds look similar to this compound(15227-42-6)Category: tetrahydroisoquinoline, numerous studies have shown that this compound(SMILES:[Cl-][Pt+2]([N]1=CC=CC=C1)([Cl-])[N]2=CC=CC=C2), has unique advantages. If you want to know more about similar compounds, you can read my other articles.

Reference:
Tetrahydroisoquinoline – Wikipedia,
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem